K
Keith C. Bible
Researcher at Mayo Clinic
Publications - 108
Citations - 16530
Keith C. Bible is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Thyroid cancer & Anaplastic thyroid cancer. The author has an hindex of 37, co-authored 105 publications receiving 12906 citations. Previous affiliations of Keith C. Bible include University of Rochester & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R. Haugen,Erik K. Alexander,Keith C. Bible,Gerard M. Doherty,Susan J. Mandel,Yuri E. Nikiforov,Furio Pacini,Gregory W. Randolph,Anna M. Sawka,Martin Schlumberger,Kathryn G. Schuff,Steven I. Sherman,Julie Ann Sosa,David L. Steward,R. Michael Tuttle,Leonard Wartofsky +15 more
TL;DR: Evidence-based recommendations are developed to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer and represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Journal ArticleDOI
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Robert C. Smallridge,Kenneth B. Ain,Kenneth B. Ain,Sylvia L. Asa,Sylvia L. Asa,Keith C. Bible,James D. Brierley,James D. Brierley,Kenneth D. Burman,Electron Kebebew,Nancy Y. Lee,Yuri E. Nikiforov,M. Sara Rosenthal,Manisha H. Shah,Ashok R. Shaha,R. Michael Tuttle +15 more
TL;DR: These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy.
Journal ArticleDOI
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C. Bible,Vera J. Suman,Julian R. Molina,Robert C. Smallridge,William J. Maples,Michael E. Menefee,Joseph Rubin,Kostandinos Sideras,John C. Morris,Bryan McIver,Jill K. Burton,Kevin P. Webster,Carolyn Bieber,Anne M. Traynor,Patrick J. Flynn,Boon Cher Goh,Hui Tang,Susan Percy Ivy,Charles Erlichman +18 more
TL;DR: Pazopanib seems to represent a promising therapeutic option for patients with advanced differentiated thyroid cancers, and the correlation of the patient's response and pazobanib concentration during the first cycle might indicate that treatment can be individualised to achieve optimum outcomes.
Journal ArticleDOI
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad,Mia D. Champion,Jan B. Egan,Winnie S. Liang,Rafael Fonseca,Alan H. Bryce,Ann E. McCullough,Michael T. Barrett,Michael T. Barrett,Katherine S. Hunt,Maitray D. Patel,Scott W. Young,Joseph M. Collins,Alvin C. Silva,Rachel M. Condjella,Matthew S. Block,Robert R. McWilliams,Konstantinos N. Lazaridis,Eric W. Klee,Keith C. Bible,Pamela E. Harris,Gavin R. Oliver,Jaysheel D. Bhavsar,Asha Nair,Sumit Middha,Yan W. Asmann,Jean Pierre A. Kocher,Kimberly A. Schahl,Benjamin R. Kipp,Emily G. Barr Fritcher,Angela Baker,Jessica Aldrich,Ahmet Kurdoglu,Tyler Izatt,Alexis Christoforides,Irene Cherni,Sara Nasser,Rebecca Reiman,Lori Phillips,Jackie McDonald,Jonathan Adkins,Stephen D. Mastrian,Pamela Placek,Aprill Watanabe,Janine LoBello,Haiyong Han,Daniel D. Von Hoff,Daniel D. Von Hoff,David Craig,A. Keith Stewart,John D. Carpten +50 more
TL;DR: FGFR2 fusions and ERRFI mutations may represent novel targets in sporadic intrahepatic cholangiocarcinoma and trials should be characterized in larger cohorts of patients with these aberrations.
Journal Article
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Keith C. Bible,Scott H. Kaufmann +1 more
TL;DR: In this article, the authors used colony-forming assays to examine the cytotoxicity resulting from combining flavopiridol with eight other antineoplastic agents in four different administration schedules in A549 human non-small cell lung carcinoma cells.